Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- CRISPR Advances June 16, 2026
- Turning Prostate Cancer from Cold to Hot: How Tiny Silica Particles Kill Tumors and Wake Up the Immune System June 16, 2026
- Killing the Last 0.1%: Targeting Cancer Persister Cells June 15, 2026
- Phase III PrTK03 Trial Results: Aglatimagene Besadenovec (CAN-2409) Improves Survival in Localized Prostate Cancer June 15, 2026
DiWB-1: A Targeted Approach to Prostate Cancer Treatment
/in Pepetide-Drug Conjugate, Preclinical Research/by MaxDiWB-1, a luteinizing hormone-releasing hormone (LHRH)-targeted peptide-drug conjugate (PDC) with PI3K inhibition properties, is an emerging candidate that may offer a new way to treat prostate cancer. Its design and mechanism suggest potential for addressing some of the limitations of current treatments, particularly for resistant cases. DiWB-1 is described as an LHRH-targeted PDC, a class […]
New Method Uses Nanoparticles to Create CAR T Cells Inside Body for Cancer Treatment
/in mRNA, Preclinical Research/by MaxPhase 1 Trial for ART-101, a Novel Radioligand Targeting PSMA in mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1/2 For a New PARP1 Inhibitor: EIK1004 (IMP1707) For mCRPC
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 1/2 Trial: MT-4561 Targeting BRD4 in Metastatic Prostate Cancer and Neuroendocrine Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxNEPC
Real-World Studies Suggest Survival Advantage with Apalutamide in mCSPC Treatment
/in Retrospective studies/by MaxPhase 2 Trial: ZG006 a New Immunotherapy for Neuroendocrine Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxPhase 3 Trial: Ifinatamab Deruxtecan (MK-2400) for metastatic Castration-Resistant Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by Max